Sarepta Therapeutics | SRPT - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
Acadia Pharmaceuticals USD 37.84M 42.45M 2026-06
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Alnylam Pharmaceuticals USD 112.6M 24.99M 2026-06
Amgen USD 4.61B 777M 2026-06
BioCryst Pharmaceuticals USD 98.46M 161.92M 2026-06
Biogen USD -243.8M 758.1M 2026-06
BioMarin Pharmaceutical USD 105.6M 24.04M 2026-06
Capricor Therapeutics USD -29.16M 2.87M 2025-12
Daiichi Sankyo JPY 85.1B 4.44B 2026-06
Eli Lilly USD 12.46B 2.68B 2026-06
Gilead Sciences USD 3.85B 1.17B 2026-06
Incyte USD 700.4M 376.22M 2026-06
Insmed USD -101.31M 98.97M 2026-06
Ionis Pharmaceuticals USD -102.29M 15.71M 2026-06
Moderna USD -815M 573M 2026-06
Nektar Therapeutics USD -38.26M 19.17M 2026-03
Neurocrine Biosciences USD 219.9M 5.3M 2026-06
Novavax USD 20.94M 100.32M 2025-12
Pfizer USD 667M 4.32B 2026-06
PTC Therapeutics USD 45.89M 127.51M 2026-03
Regeneron Pharmaceuticals USD 1.42B 675.7M 2026-06
Roche Holding CHF 11.46B 1.91B 2026-06
Sangamo BioSciences USD -33.51M 12.77M 2024-06
Sanofi EUR 2.38B 449M 2026-06
Sarepta Therapeutics USD 13.29M 345.14M 2026-06
Tectonic Therapeutic USD -27.3M 5.78M 2026-03
Ultragenyx Pharmaceutical USD -75M 141M 2026-06
Vertex Pharmaceuticals USD 1.27B 129.9M 2026-06